Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Financial Results
    • Novartis India Q4...

    Novartis India Q4 profit falls 26 percent to Rs 20 crore

    GarimaWritten by Garima Published On 2019-05-25T09:30:35+05:30  |  Updated On 25 May 2019 9:30 AM IST
    Novartis India Q4 profit falls 26 percent to Rs 20 crore

    Novartis India's board has recommended a dividend of 200 per cent (Rs 10 per equity share of Rs 5 each) for the year ended March 31, 2019.


    New Delhi: Drug firm Novartis India Thursday reported 26.21 per cent decline in net profit at Rs 19.53 crore for the quarter ended March 31, 2019.


    The company posted a profit of Rs 26.47 crore in the year-ago period, Novartis India said in a BSE filing.


    Revenue from operations for the latest quarter stood at Rs 110.38 crore as against Rs 125.32 crore in the same period of 2017-18.


    Read Also: Novartis plans gene therapy price lower than $4 million to $5 million range


    For the entire 2018-19, net profit was Rs 51.77 crore as compared to Rs 78.36 crore during the previous year.


    Revenue from operations for the last fiscal stood at Rs 490.68 crore as against Rs 563.89 crore in 2017-18.


    The company's board has recommended a dividend of 200 per cent (Rs 10 per equity share of Rs 5 each) for the year ended March 31, 2019.


    Read Also: Japan: Novartis gets Government nod for cancer treatment Kymriah at cost of $305800

    BSEDrug firm Novartis Indiafourth quarterIndiaNew DelhiNovartisNovartis Indianovartis profit fallsNovartis Q4Q4revenueShares of Novartis India
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok